ALEA eCRF is an electronic Case Report Forms service for data collection in clinical trials. It is a comprehensive, user friendly forms service which can be used with a standard browser running on any computer connected to the internet. The current version is suitable for virtually any trial in health care. Within ALEA eCRF, the components share a database for storing and retrieving information about the trial, and a separate database for storing and retrieving patient data. 

The randomisation service includes flexible form definition, unlimited stratification factors, unlimited number of treatments, blocked randomisation, minimisation, unequal allocation schemes, multi step randomisation, a simulation service which produces a comprehensive validation report and more. It allows for re-use of components at the level of questions, forms and complete studies.

The Notification Service Module is responsible for the distribution of notifications after randomisation. These may be sent by email, fax, or printed directly on a printer attached to the randomisation server network. Most notifications are triggered by the randomisation of a patient into the trial and such notifications may be sent to, for example, the responsible clinician, a study monitor at the sponsoring organisation (a pharmaceutical company), or a pharmacist who will prepare the study medication. As well as notifications are send after the randomisation, the Notification Service Module can distribute periodic status reports on the trial or generate reports after specific events within the trial.

ALEA eCRF is an electronic Case Report Forms service for the data collection in clinical trials. It provides a comprehensive, user friendly forms service which can be used in a standard browser running on any computer connected to the internet. ALEA has been built as a series of industry grade components from Microsoft, which have been customized for the specific purpose of clinical trials data management. ALEA is suitable for virtually any trial and is used in over 700 trials and 7.000 sites worldwide.